Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023
In conclusion, patients with hematologic malignancies who have participated in early-phases clinical trials over the past 15 years have achieved variable therapeutic response rates, acceptable risk/benefit ratio and potentially significant therapeutic advantages. This study provides framework material for hematologists to further discuss clinical trial participation with their patients.
Authors
- Emily Linda Alouani (ORCID: https://orcid.org/0000-0002-2303-118X)
- Sophie C. Postel-Vinay (ORCID: https://orcid.org/0000-0001-5562-1857)
- Jean‐Baptiste Micol (ORCID: https://orcid.org/0000-0003-0934-294X)
- Stéphane de Botton (ORCID: https://orcid.org/0000-0002-8126-4942)
- Kaïssa Ouali (ORCID: https://orcid.org/0000-0002-8269-3001)
- Anas Gazzah (ORCID: https://orcid.org/0000-0002-6866-6787)
- Christophe Willekens (ORCID: https://orcid.org/0000-0001-9814-8537)
- Matteo Guerra (ORCID: https://orcid.org/0000-0001-5040-3455)
- Vincent Ribrag (ORCID: https://orcid.org/0000-0002-5221-353X)
- Thomas Hueso (ORCID: https://orcid.org/0000-0003-3354-332X)
- Rastislav Bahleda (ORCID: https://orcid.org/0009-0001-8245-0544)
- Jean‐Marie Michot (ORCID: https://orcid.org/0000-0003-3482-3331)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
- Capucine Baldini
- Alina Danu
- Christophe Massard
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-09-21
- DOI
- https://doi.org/10.1111/ejh.14307
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00